Fig. 4From: Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trialCST (μm) changes at weeks 4, 8 and 12. Mean (± SE) CST decreased from baseline by 77.64 ± 20.65 (p = 0.0039), 106.54 ± 20.65 (p < 0.0001) and 121.73 ± 20.65 (p < 0.0001) at 4, 8, and 12 weeks, respectivelyBack to article page